The Cleveland Clinic
In this preliminary observation study, the investigators will assess muscle function in terms of muscle strength and leverage imaging (MRI) and spectroscopy (31P-MRS) based techniques to assess longitudinal changes in muscle volume, quality and metabolic function in patients with T2D and obesity prescribed to semaglutide therapy. The patients will be evaluated at three time points: 1) baseline, 2) 3-month and 3) 6-month after the therapy. These longitudinal changes will then be compared and correlated with changes in physical measurements such as BMI and patient reported outcome measures (PROMs). The primary aim of our study is to investigate the longitudinal effects of semaglutide therapy on patients with T2D and obesity, on skeletal muscle strength, muscle volume, quality and metabolic function.
Type 2 diabetes (T2D),characterized by insulin resistance and abnormal metabolic functions, is the most prevalent metabolic syndrome disease (1). Excess weight gain is the number one risk factor for development of T2D, in which 85% of individuals with T2D are either overweight or obese (2). While weight management through diet and exercise is foundational for treatment, genetic and environmental factors pose challenges (3). Recently, once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), and tirzepatide, a gastric inhibitory peptide/glucagon-like peptide-1…
Inclusion Criteria: 1. Gender: men and women 2. Ethnicity: all ethnic groups 3. Age between 45 and 75 years 4. BMI ≥ 30 kg/m2 and BMI \< 45 kg/m2 5. Diagnosis of Type 2 Diabetes (T2D) with HbA1c levels between 7% and 10.5%. 6. Starting subcutaneous semaglutide for clinically indicated T2D management. 7. Ability and willingness to participate in the study for its full duration. 8. Provision of informed consent for participation in research. Exclusion Criteria: 1. Previous intolerance or allergy to any semaglutide-based therapy. 2. History of prior intolerance to any GLP-1RA or GIP/GLP-1RA. 3…
31P-MRS and MRI for patients with Type 2 Diabetes and obesity prescribed to semaglutide therapy
Arctuva estimate
Verify or correct the compensation shown for this listing.